Topical immunomodulators—progress towards treating inflammation, infection, and cancer

This publication has 67 references indexed in Scilit:

• Application of a Topical Immune Response Modifier, Resiquimod Gel, to Modify the Recurrence Rate of Recurrent Genital Herpes: A Pilot Study
  The Journal of Infectious Diseases, 2001
• Potentiating Effect of Imiquimod in the Treatment of Verrucae Vulgares in Immunocompromised Patients
  Published by Medical Journals Sweden AB ,2000
• Adjuvant Activities of Immune Response Modifier R-848: Comparison with CpG ODN
  Cellular Immunology, 2000
• The Imidazoquinolines, Imiquimod and R-848, Induce Functional, but Not Phenotypic, Maturation of Human Epidermal Langerhans' Cells
  Clinical Immunology, 2000
• CpG DNA rescues B cells from apoptosis by activating NFκB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway
  International Immunology, 1999
• Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream
  Journal of the American Academy of Dermatology, 1999
• The Instructive Role of Innate Immunity in the Acquired Immune Response
  Science, 1996
• CpG motifs in bacterial DNA trigger direct B-cell activation
  Nature, 1995
• Interferon treatment enhances the expression of underphosphorylated (biologically-active) retinoblastoma protein in human papilloma virus-infected cells through the inhibitory TGFβ1/IFNβ cytokine pathway
  Antiviral Research, 1994
• Papillomaviruses and human oncogenesis
  Current Opinion in Genetics & Development, 1992